A Mental 🧠 Health Revolution — 2 Stocks to Watch
These biotech companies are meeting critical needs!
Note: Please read our disclaimer at the bottom of the article.
#StrongHands 🙌 #BOP 🚀 Nation Update ️️️️️️️️️️️️️️️️️️️❤️️
Hi, I’m Paul Mampilly.
Welcome to my company's Substack, where we provide daily coverage of #OGI (opportunity, growth, and innovation) market trends, macro level analysis, and stock picks.
Like our name suggests, at ATG Digital, we go Against the Grain to support everyday people on their investing journeys.
ATG also represents seeing the world for what is abundantly clear to see — an opportunity for incredible growth and the BRIGHT and PROSPEROUS future that lies ahead.
To aid you on your journey to financial freedom, we have five paid plans starting at $9.99 for you to consider.
With a subscription you get:
Premium Content: Weekly market and stock updates via email newsletter.
Stock Picking Guidance: Flash (buy/sell) alerts with targeted price points.
Model Portfolio Access: Access to LIVE portfolios.
Webinars: Private events with the team based on ideas preselected by you.
(Purple Tier Members)
Just visit atgdigital.media to see which plan is the best fit for your journey!
Substack 🥞 subscribers: 5,765 (+2)
Paul: The Biotech Revolution No One Is Talking About 🤫
Mental health is one of the greatest unmet needs today.
According to the National Institute of Mental Health Disorders, research shows that 26% of people 18 and older suffer from a diagnosable mental health condition.
And nearly 10% suffer from some form of a depressive disorder.
So it should come as no surprise that antidepressant sales are estimated to be $16.6 billion in 2023.
Antidepressants have helped many people. Still, many of these medications have issues.
For many, they simply don’t work, or don’t work well enough to continue use — between 50% to 66% of the patients on drug therapy don’t experience recovery and relapse.
Often, patients have to cycle through one medication and into another to continue seeing an effect.
And side effects can be serious for some.
Many pharmaceutical companies have given up on developing drugs for depression, because drugs for mental health have a high failure rate.
Psilocybin Drugs — A Revolution for Mental Health Drugs ⭐
However, one group of companies has taken on the challenge of developing new drugs for mental health and depression.
These companies are biotechnology companies using psychedelic compounds like psilocybin.
Psilocybin is a chemical compound found in mushrooms.
When used with guidance and in limited doses, psilocybin has shown dramatic effects in people with mental health disorders.
And after a decade of development, psilocybin drugs could revolutionize the mental health drug sector.
70% Rates of Remission Are Extraordinary 👍
Recently, two of the companies in our portfolios reported extraordinary results from clinical trials using their psilocybin-based drugs.
CYB003, a psilocybin-based treatment being tested by Cybin Inc. (NYSE: CYBN), showed a 70% remission rate in a trial after just six weeks with major depressive disorder (MDD).
Mind Medicine (MindMed) Inc. (Nasdaq: MNMD) — another company focused on mental health using psilocybin — had equally dramatic results in general anxiety disorder (GAD).
We’re currently up over 100% on this position in just two months!
MNMD 0.00%↑’s MM-120 drug in clinical trials showed a 78% response rate by week four.
Both these results are extraordinary for how many people respond to these drugs and how quickly they do it — based on my prior experience with researching these types of drugs.
The side effect profile of these drugs is also benign, relative to the side effects of old school antidepressant drugs.
The Potential Market for These Drugs Is Huge 📈
I believe these drugs and companies could bring about a revolution for mental health because of the response rate, speed, side effect profile and ease of use.
If that’s right, CYBN 0.00%↑ and MNMD 0.00%↑ will begin to anticipate these drugs becoming widely prescribed to patients.
If these drugs were to capture 10% of the market for antidepressants, its sales would be $1.66 billion.
That’s huge compared to the market capitalization of these companies today.
CYBN 0.00%↑ is a microcap company valued at $158 million.
MNMD 0.00%↑ is slightly bigger with a market capitalization of $248 million.
If their drugs survive clinical testing, FDA approval, and become widely prescribed, their stocks should soar.
Risky — But Potential for 1,000%+ Gains
Now, truthfully, there’s still a lot of work left for CYBN 0.00%↑ and MNMD 0.00%↑ to do. Clinical trials are tricky, and the FDA often delays new drugs.
They’ll also need more money to develop these drugs fully.
Bottom line, these stocks are risky. Still, with results this good, these stocks have incredible potential to go up by thousands of percent.
CYBN 0.00%↑ and MNMD 0.00%↑ are in our Diamond Tier portfolio, which focuses on small/microcap stocks and crypto.
To subscribe today — or to check out our other subscription options — click here!
#GBC100: Monday, March 11, 2024
The #GBC100 is up 0.27% today.
With markets shifting in our direction, there isn’t anything new to write about. So, just to let you know, we won’t always be commenting on the performance of the #GBC100 daily.
However, we’ll be updating the performance, and we want to remind folks that our goal is to turn the #GBC100 into an ETF that offers a one-stock way to invest the ATG way — in innovation and growth.
To learn more or express your support for the launch of an ETF (by completing a poll), click here.
Tomorrow: Dan will cover a cloud-based company we’re keeping an eye on. 👀
Every week, the ATG team posts videos to our YouTube channel. 📺
And just the other day, Paul received this comment on one:
Julie, we’re so happy to hear this! And regarding what you said about Paul, you hit the nail on the head. 🔨
After all, we created ATG Digital with the goal of helping “folks on the street.” 😉
On Monday, March 11, 2024, we hope to continue helping our community!
❤️️ This Substack made — by US, for YOU — with love. ❤️️
Questions? Concerns? 🤔 Look Below 👇
Have questions or trouble accessing your account? Please reach out to us at info@atgdigital.media or schedule a call, and our Customer Support team will be happy to help.
You can also check our FAQ page on our website for an up-to-date list of questions and answers. Your question may have been addressed there.
*Please be advised that customer support calls are limited to 15 minutes and will strictly cover your membership subscription and billing needs only. Any calls that are disrespectful in nature may be subject to immediate termination.
Join us, be #BOP 🚀, be #StrongHands 🙌, #GoATG! ️️❤️️
Disclaimer/Legal Stuff Written in Plain English
What you read/watch/hear is OPINION, not financial/investment advice. Treat it no different than when you read/watch/hear your favorite author/YouTuber/podcaster. Despite our best efforts, we get things wrong and make mistakes. Investing is risky. There is no guarantee you will make money. Your investments may lose value. That’s RISK. Past performance is no guarantee of future results. Employees, contractors, and owners of ATG Digital, LLC own/trade/transact in the stocks, options, and crypto that are the subject of our trade alerts, updates, reports, and commentaries. We cannot give you personalized financial advice because we are NOT financial advisors. It’s on you to decide how much/when/what to buy/sell based on YOUR financial needs, plans, and risk preferences. There are no guarantees. Loss of your capital is an outcome that you should evaluate carefully with a financial advisor before you trade, speculate, or invest. It's your money and your responsibility.